Supplementary Tables 1-4 from Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST
journal contribution
posted on 2023-04-03, 15:00 authored by Hao Xu, Liang Chen, Yang Shao, Dongqin Zhu, Xiaofei Zhi, Qiang Zhang, Fengyuan Li, Jianghao Xu, Xisheng Liu, Zekuan XuSupplementary table 1 Univariate analysis of influence factors of concordance between ctDNA and tissue DNA detections; Supplementary table 2 Concordance analysis between ctDNA and tissue DNA detections in genetic analysis (Tumor size>10cm, n=23); Supplementary table 3 Concordance analysis between ctDNA and tissue DNA detections in genetic analysis (Ki-67>5%, n=19); Supplementary table 4 Univariate analysis of influence factors of prognosis (Log-rank Test)
Funding
National Natural Science Foundation of China
Jiangsu Key Medical Discipline
Priority Academic Program
Nanjing Medical University
Natural Science Foundation of Jiangsu Province
History
ARTICLE ABSTRACT
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor of digestive tract. In the past, tissue biopsy was the main method for the diagnosis of GISTs. Although, circulating tumor DNA (ctDNA) detection by next-generation sequencing (NGS) may be a feasible and replaceable method for diagnosis of GISTs. We retrospectively analyzed the data for ctDNA and tissue DNA detection from 32 advanced GIST patients. We found that NGS obviously increased the positive rate of ctDNA detection. ctDNA detection identified rare mutations that were not detected in tissue DNA detection. Tumor size and Ki-67 were significant influencing factors of the positive rate of ctDNA detection and concordance between ctDNA and tissue DNA detection. In all patients, the concordance rate between ctDNA and tissue DNA detection was 71.9%, with moderate concordance, but the concordance was strong for patients with tumor size > 10 cm or Ki-67 > 5%. Tumor size, mitotic figure, Ki-67, and ctDNA mutation type were the significant influencing factors of prognosis, but only tumor size and ctDNA mutation type, were the independent prognostic factors for advanced GIST patients. We confirmed that ctDNA detection by NGS is a feasible and promising method for the diagnosis and prognosis of advanced GIST patients. Mol Cancer Ther; 17(1); 290–6. ©2017 AACR.Usage metrics
Keywords
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC